Fed and Fasting Bioequivalence Studies
A meal can double a drug’s absorption or halve it. Fed and fasting bioequivalence studies prove your product tracks the reference in both states — one facility, one validated method, both arms.
Range (90% CI)
Test Meal
Methods
Facility
What Are Fed and Fasting Bioequivalence Studies?
A fasting bioequivalence study doses subjects after an overnight fast of at least 10 hours — the default and most sensitive condition for detecting formulation differences. A fed bioequivalence study doses the same products 30 minutes after the start of a standardized high-fat, high-calorie breakfast of roughly 800 to 1,000 kilocalories, about half of them from fat, to show that equivalence holds when the product is taken with food.
Food changes almost everything the gastrointestinal tract does to a dose: gastric pH and emptying, bile secretion, splanchnic blood flow, and the physical environment a tablet disintegrates in. For lipophilic molecules and modified-release forms, those shifts can push Cmax and AUC outside the 80.00–125.00% window even when the fasting study passes comfortably. That is why regulators generally expect both conditions for immediate-release orals, unless the reference label restricts dosing to an empty stomach.
We run fasting and fed arms at our DCGI-mandated centre in Pune with test meals standardized to the regulatory composition, supervised complete consumption within the mandated window, and precisely timed dosing — followed by in-house LC-MS/MS bioanalysis. Both arms use the same validated method and the same clinical team, so the fed result reads cleanly against the fasting result.
A crossover study comparing one formulation dosed fasting versus fed. It quantifies how much a meal changes the rate and extent of absorption, and its outcome shapes the product’s labelled dosing instructions.
A crossover study comparing test and reference products, both dosed after the standardized high-fat meal. It confirms the generic remains bioequivalent under fed conditions, not only on an empty stomach.
Fasting vs Fed Bioequivalence Studies
Same statistics, different physiology — each condition answers a question the other cannot.
| Aspect | Fasting BE Study | Fed BE Study |
|---|---|---|
| Dosing condition | After an overnight fast of at least 10 hours | Dosed 30 minutes after the start of a standardized high-fat meal of about 800–1,000 kcal, roughly 50% from fat |
| What it detects | Formulation differences under the most sensitive, least variable condition | Food-driven differences in release and absorption between test and reference |
| When required | Default for nearly all orally administered products | Immediate-release orals unless the label restricts to an empty stomach; virtually all modified-release products |
| Typical design | Two-period, two-sequence crossover with a washout of at least 5 half-lives | The same crossover design, with identical meal control in every period |
| Acceptance criteria | 90% CI of Cmax & AUC ratios within 80.00–125.00% | 90% CI of Cmax & AUC ratios within 80.00–125.00% |
When Regulators Expect a Fed Study
Immediate-Release Orals
US FDA and most agencies recommend fasting plus fed BE for IR products, except where the reference label says the drug must be taken on an empty stomach.
Modified-Release Products
Fed dosing stress-tests the release mechanism — the risk of dose dumping makes the fed study non-negotiable for MR and ER forms.
Label-Driven Fed Dosing
When the reference product is labelled to be taken with food, the fed study becomes the primary demonstration of bioequivalence.
High Food-Effect Risk Molecules
Lipophilic, poorly soluble drugs — where a meal materially changes solubilization — justify fed data even where a single-study pathway exists.
Fed & Fasting Study Process
- 01
Design & Regulatory Mapping
Product-specific guidance review, single-study versus two-study strategy, meal composition, and sampling schedule fixed with your team.
- 02
Ethics Approval
Independent ethics committee submission and clearance handled end to end by our regulatory team.
- 03
Standardized Meal & Dosing
Overnight fast, controlled high-fat breakfast consumed within the mandated window, dosing at the 30-minute mark, and timed sampling through the full profile.
- 04
LC-MS/MS Bioanalysis & PK
In-house analysis on the validated method, pharmacokinetic parameters, and fed-versus-fasting statistics.
- 05
Report & Submission Support
A dossier-ready study report with the statistical outputs your regulatory pathway requires.
Why Sponsors Choose Us for Fed & Fasting BE
- DCGI-mandated, ANVISA-approved clinical research facility
- Fasting and fed arms run by the same unit, method, and team
- High-fat test meals standardized and supervised to regulatory composition
- 75+ validated LC-MS/MS methods across dosage forms
- Crossover logistics that keep washout and period scheduling tight
- Dossier-ready reports designed for US FDA, EMA, and CDSCO review
Fed & Fasting Studies — Frequently Asked Questions
1. What is a food effect study?
2. What is the difference between fed and fasting bioequivalence studies?
3. What meal is used in a fed bioequivalence study?
4. When is a fed bioequivalence study required?
5. How long is the washout period between study periods?
6. Can a food effect cause a bioequivalence study to fail?
More BA/BE Studies Services
Every study type under one roof — explore the rest of our ba/be studies capabilities.
Pilot BE Studies
Small, fast studies that measure formulation variability before you commit to a pivotal trial.
Patient BE Studies
BE studies in patients when healthy-volunteer dosing is unsafe — cytotoxic, oncology, and high-risk products.
Biosimilar PK Studies
Comparative pharmacokinetic similarity studies for biosimilars, backed by large-molecule LC-MS/MS.
Population BE
Designs and statistics for when average bioequivalence alone cannot answer the prescribability question.
Postmenopausal Studies
Special-population BA/BE studies in postmenopausal women for hormone and women’s-health products.
Transdermal Patch BE
TDS bioequivalence programs covering PK, adhesion, irritation, sensitization, and residual drug analysis.
Nasal Spray BE
Device-based BE combining in vitro performance testing with in vivo PK under a weight-of-evidence approach.
Bioanalytical Services
LC-MS/MS method development, ICH M10 validation, and study sample analysis — the lab behind every study.
Discuss Your Fed & Fasting BE Requirement
Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.